Yuekang Pharmaceutical announced that the company plans to use 45 million yuan of overraised capital to invest in the new project “Small Nucleic Acid Drug Research and Development Project”. The total investment amount of the project is consistent with the amount of overfunded capital to be invested this time, and all of the capital will come from raised funds. The project includes three small nucleic acid drugs under development: YKYY015 for hypercholesterolemia, etc., with the goal of completing phase II clinical enrollment; YKYY029 for high blood pressure, which aims to invest 10 million yuan to complete phase II clinical enrollment; YKYY032 for hyperlipoproteinemia, which aims to invest 11 million yuan to complete 25% of phase II clinical enrollment. The matter has been reviewed and approved by the board of directors of the company, the sponsor issued a consent verification opinion, and there are risks such as the project development process falling short of expectations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.